ArticleJournal of immunology research2015
A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Immuno-PET imaging of mesothelin in ovarian cancer withBiomarker research · 2026Article
- Theranostic Potential of [177Lu]Lu-DOTA-Tocilizumab in Multiple Myeloma: A Preclinical Evaluation.Anti-cancer agents in medicinal chemistry · 2026Article
- Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.Cancer medicine · 2025Review
- Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation.Molecular cancer · 2025Article
- Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.Frontiers in immunology · 2024Review
- Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment.Frontiers in drug delivery · 2024Review
- One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.International journal of molecular sciences · 2023Article
- Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target.Pathology oncology research : POR · 2023Article
- Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.Frontiers in immunology · 2023Article
- Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.International journal of molecular sciences · 2021Review
- Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?International journal of molecular sciences · 2021Review
- Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography.Journal of clinical medicine · 2021Review
- A NovelLife (Basel, Switzerland) · 2021Review
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2020Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.Cancers · 2020Review
- Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma.Frontiers in oncology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesothelin (MSLN) is a 40-kDa cell differentiation-associated glycoprotein appearing with carcinogenesis and is highly expressed in many human cancers, including the majority of pancreatic adenocarcinomas, ovarian cancers, and mesotheliomas, while its expression in normal tissue is limited to mesothelial cells lining the pleura, pericardium, and peritoneum. Clone 11-25 is a murine hybridoma secreting monoclonal antibody (mAb) against human MSLN. In this study, we applied the 11-25 mAb to in vivo imaging to detect MSLN-expressing tumors. In in vitro and ex vivo immunochemical studies, we demonstrated specificity of 11-25 mAb to membranous MSLN expressed on several pancreatic cancer cells. We showed the accumulation of Alexa Fluor 750-labeled 11-25 mAb in MSLN-expressing tumor xenografts in athymic nude mice. Then, 11-25 mAb was labeled with (64)Cu via a chelating agent DOTA and was used in both in vitro cell binding assay and in vivo positron emission tomography (PET) imaging in the tumor-bearing mice. We confirmed that (64)Cu-labeled 11-25 mAb highly accumulated in MSLN-expressing tumors as compared to MSLN-negative ones. The (64)Cu-labeled 11-25 mAb is potentially useful as a PET probe capable of being used for wide range of tumors, rather than (18)F-FDG that occasionally provides nonspecific accumulation into the inflammatory lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.